| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
1 The King’s MND Care and Research Centre, Institute of Psychiatry, Guy’s King’s and St Thomas’s School of Medicine, and King’s College Hospital, London, UK
2 Department of Respiratory Medicine, King’s College Hospital, and Guy’s King’s and St Thomas’s School of Medicine, London UK
Correspondence to:
Correspondence to:
Professor P N Leigh
King’s MND Care and Research Centre, Department of Neurology, Institute of Psychiatry and Guy’s King’s and St Thomas’s School of Medicine, PO Box 41, Institute of Psychiatry, Denmark Hill, London SE5 8AF, UK;
n.leigh@iop.kcl.ac.uk
| The first 150 words of the full text of this article appear below. |
The management of motor neurone disease (MND) has evolved rapidly over the last two decades. Although still incurable, MND is not untreatable. From an attitude of nihilism, treatments and interventions that prolong survival have been developed. These treatments do not, however, arrest progression or reverse weakness. They raise difficult practical and ethical questions about quality of life, choice, and end of life decisions.
Coordinated multidisciplinary care is the cornerstone of management and evidence supporting this approach, and for symptomatic treatment, is growing.1–3 Hospital based, community rehabilitation teams and palliative care teams can work effectively together, shifting emphasis and changing roles as the needs of the individuals affected by MND evolve. In the UK, MND care centres and regional networks of multidisciplinary teams are being established. Similar networks of MND centres exist in many other European countries and in North America.
Here, we review current practice in relation to diagnosis, genetic
Relevant Article
J. Neurol. Neurosurg. Psychiatry 2003 74: iv13-iv17.
This article has been cited by other articles:
|
|
 |
|
  J T H Van Asseldonk, L H Van den Berg, S Kalmijn, R M Van den Berg-Vos, C H Polman, J H J Wokke, and H Franssen Axon loss is an important determinant of weakness in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 743 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Eng Management guidelines for motor neurone disease patients on non-invasive ventilation at home Palliative Medicine, March 1, 2006; 20(2): 69 - 79. [Abstract] [PDF]
|
|
|
|
|
|
M Hutchinson, R Galvin, B Sweeney, T Lynch, R Murphy, J Redmond, B J Traynor, and O Hardiman Effect of a multidisciplinary clinic on survival in amyotrophic lateral sclerosis * Author's reply J. Neurol. Neurosurg. Psychiatry, August 1, 2004; 75(8): 1208 - 1209. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
